Circulating Levels of Resistin and Risk of Type 2 Diabetes in Men and Women: Results From Two Prospective Cohorts

OBJECTIVE—The purpose of this study was to investigate the role of circulating resistin levels in the development of type 2 diabetes using two prospective cohorts of well-characterized men and women. RESEARCH DESIGN AND METHODS—We conducted two prospective case-control studies nested in the Women's Health Study (WHS) and Physicians’ Health Study II (PHS II). In the WHS, during a median of 10-years of follow-up, 359 postmenopausal women, who were apparently healthy at baseline and later developed type 2 diabetes, were prospectively matched with 359 healthy control subjects. In the PHS II, with 8 years of total follow-up, 170 men, who were apparently healthy at baseline and later developed type 2 diabetes, were matched with 170 healthy control subjects. Control subjects were matched by age, race, and time of blood draw. RESULTS—Resistin levels at baseline were significantly higher in women than in men (P = 0.003) and in case patients than in control subjects for both women (P < 0.001) and men (P = 0.07). After adjustment for matching factors, physical activity, alcohol intake, smoking, and family history of diabetes, the relative risk of type 2 diabetes comparing the highest to the lowest quartile of resistin in women was 2.22 ([95% CI 1.32–3.73]; Ptrend = 0.002). This association was attenuated after further adjustment for BMI (1.51 [0.86–2.65]; Ptrend = 0.20) or C-reactive protein (1.18 [0.68–2.07]; Ptrend = 0.60). A similar but weaker pattern was observed in men. CONCLUSIONS—Elevated levels of circulating resistin were significantly related to increased risk of type 2 diabetes, which appears to be partially accounted for by adiposity and the inflammatory process.

[1]  JoAnn E Manson,et al.  Accuracy of Administrative Coding for Type 2 Diabetes in Children, Adolescents, and Young Adults , 2007, Diabetes Care.

[2]  H. Sul,et al.  Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Manson,et al.  Hemoglobin A1c level and future cardiovascular events among women. , 2004, Archives of Internal Medicine.

[4]  C. Hennekens,et al.  Design of Physicians' Health Study II--a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. , 2000, Annals of epidemiology.

[5]  U. Smith,et al.  Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. , 2001, Biochemical and biophysical research communications.

[6]  R. Busse,et al.  Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin , 2006, Diabetologia.

[7]  J. Manson,et al.  Vitamin E and Risk of Type 2 Diabetes in the Women’s Health Study Randomized Controlled Trial , 2006, Diabetes.

[8]  U. Smith,et al.  Resistin, an Adipokine with Potent Proinflammatory Properties1 , 2005, The Journal of Immunology.

[9]  L. J. Hardies,et al.  Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.

[10]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[11]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[12]  A. Ruokonen,et al.  Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. , 2007, European journal of endocrinology.

[13]  M. Lazar,et al.  Regulation of Fasted Blood Glucose by Resistin , 2004, Science.

[14]  A. Barnett,et al.  Increased resistin gene and protein expression in human abdominal adipose tissue. , 2002, The Journal of clinical endocrinology and metabolism.

[15]  F. Hu,et al.  Total and High-Molecular-Weight Adiponectin and Resistin in Relation to the Risk for Type 2 Diabetes in Women , 2008, Annals of Internal Medicine.

[16]  J. Olefsky,et al.  Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. , 2004, The Journal of clinical investigation.

[17]  T. Yoshikawa,et al.  Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[18]  G. Norata,et al.  Plasma resistin levels correlate with determinants of the metabolic syndrome. , 2007, European journal of endocrinology.

[19]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[20]  N. Cook,et al.  Baseline characteristics of participants in the Women's Health Study. , 2000, Journal of women's health & gender-based medicine.

[21]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[22]  K. Park,et al.  Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. , 2004, The Journal of clinical endocrinology and metabolism.

[23]  Toru Egashira,et al.  Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. , 2007, Metabolism: clinical and experimental.

[24]  J. Manson,et al.  A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. , 2004, Diabetes care.